Pruritus NHP Model

Name: China Pruritus NHP Model - Pruritus NHP Model Research | PRISYS
Brand: Prisys
SKU: 259788970

Explore Prisys Biotech's Pruritus NHP Model, utilizing IL-31 induction for clinically translatable research in pruritic skin conditions. Discover its advantages for drug development.

Send Inquiry

Product Introduction

Pruritus, commonly known as itching, is a prevalent symptom in several dermatological conditions, including atopic dermatitis (AD). The chronic nature of pruritus often leads to skin lesions due to excessive scratching, significantly impacting the quality of life of affected individuals. Research into pruritus mechanisms and therapies is crucial for improving treatment outcomes.

Cause: Interleukin-31 (IL-31), a cytokine associated with inflammatory and immune responses, is a key mediator of pruritus. Overexpression or recombinant administration of IL-31 induces pruritic skin conditions in various species, resembling human AD. This cytokine acts through its receptor, IL-31RA, triggering neural pathways that result in the sensation of itch.

Advantages of Non-Human Primate (NHP) Models for Pruritus Research:

•Genetic Homology: NHPs, such as Macaca mulatta, exhibit high genetic homology to humans, with IL-31 and IL-31RA sequence homologies of 93% and 94%, respectively. This enhances the translatability of findings to human conditions.

•Physiological Similarity: NHPs closely mimic human immunological and dermatological responses, providing a robust platform for studying pruritus mechanisms.

•Clinical Relevance: The IL-31-induced pruritus model in NHPs reflects the chronic nature and clinical presentation of pruritus observed in humans, enabling the evaluation of antipruritic and anti-inflammatory therapies with greater predictive accuracy.

Advantages of NHP Models Compared to Mouse Models for Pruritus Research:

•Improved Translatability: While mice exhibit IL-31 and IL-31RA sequence homologies of 31% and 61% to humans, NHPs offer a far closer genetic match.

•Complex Behavioral Responses: NHPs display sophisticated scratching and behavioral patterns, providing insights into both physiological and psychological aspects of pruritus.

•Enhanced Immunological Insights: The immune system of NHPs is more similar to humans than that of mice, allowing for a more accurate assessment of immunomodulatory treatments.

Study design and clinical endpoints

Prisys Biotech's Pruritus is induced by administering cynomolgus IL-31 (cyIL-31) through intradermal injections in the exterior/lateral thigh region.

Study design：

•Induction Method: Pruritus is induced by administering cynomolgus IL-31 (cyIL-31) through intradermal injections in the exterior/lateral thigh region.

•Monitoring: Behavioral analysis, including AI-driven pruritus counting, quantifies scratching episodes and duration as primary endpoints.

•Timeline: Evaluations are conducted pre- and post-treatment administration (TA) to assess the efficacy of candidate drugs.

Clinical endpoints:

•AI-based NHP Behavior Analysis System

•Reduction in scratching frequency and duration

•Amelioration of skin lesions

•Biomarker analysis for inflammation and neural sensitization

Species	IL-31 sequence homology (vs Human)	IL-31RA sequence homology (vs Human)
Human	100%	100%
Monkey*	93%	94%
Mouse	31%	61%

key result and figure legend

The IL-31-induced pruritus model demonstrates a significant increase in scratching behavior post-injection, mimicking human pruritic conditions. Administration of therapeutic agents effectively reduces both the frequency and duration of pruritus, as shown in the accompanying figures:

Hot Tags: pruritus nhp model, research, study, monkey, gene therapy, antibody PD pharmacology, NHP biosafety pharmacology, antibody PK pharmacology, NHP pharmacokinetics pharmacology, NHP Lung Fibrosis, PK pharmacology

Atopic Dermatitis NHP Model

Hemophilia A Model